<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453737</url>
  </required_header>
  <id_info>
    <org_study_id>14-002566</org_study_id>
    <nct_id>NCT02453737</nct_id>
  </id_info>
  <brief_title>A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca</brief_title>
  <official_title>A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label phase II study to determine the safety and efficacy of a novel 3&#xD;
      fraction daily dosing regimen for accelerated partial breast irradiation (APBI) for early&#xD;
      invasive and noninvasive breast cancer. The three techniques utilized are recognized as&#xD;
      standard options for the delivery of APBI, and there is no evidence that either technique is&#xD;
      superior or inferior to any other. The APBI technique utilized will be at the physician's&#xD;
      discretion and will be based on technical considerations, availability at the treating&#xD;
      radiation facility, insurance coverage, as well as patient preference.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 16, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the rate of adverse cosmesis (defined as fair or poor cosmesis) compared to baseline</measure>
    <time_frame>Baseline, 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Catheter-based brachytherapy APBI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7 Gy x 3 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3D-CRT APBI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7.3 Gy x 3 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton APBI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7.3 Gy x 3 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy APBI</intervention_name>
    <arm_group_label>Catheter-based brachytherapy APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3D-CRT (photon) APBI</intervention_name>
    <arm_group_label>3D-CRT APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton APBI</intervention_name>
    <arm_group_label>Proton APBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female Age ≥ 50 years at diagnosis&#xD;
&#xD;
          -  Grade 1-3 invasive ductal, mucinous, tubular, colloidal, or pure ductal carcinoma in&#xD;
             situ (DCIS) measuring ≤ 2cm (clinical stage T1).&#xD;
&#xD;
          -  Estrogen Receptor (ER)+ (ER- DCIS meeting other eligibility criteria are eligible)&#xD;
&#xD;
          -  Unicentric: Patients with microscopic multifocality are eligible as long as the total&#xD;
             pathologic tumor size is &lt;2cm.&#xD;
&#xD;
          -  Surgical treatment of the breast must have been lumpectomy.&#xD;
&#xD;
          -  The final margins of the resected specimen must be histologically free of tumor.&#xD;
&#xD;
          -  Pathologically node negative Note: For patients with T1a, T1b, T1c invasive breast&#xD;
             cancer (except T1mi), an axillary staging procedure should be performed (either&#xD;
             sentinel lymph node biopsy alone or axillary dissection and the axillary node must be&#xD;
             pathologically negative). Patients with N0 (i+) tumors on sentinel lymph node mapping&#xD;
             or dissection (i.e., if the tumor deposit is 0.2mm or less as determined by&#xD;
             immunohistochemistry or hematoxylin and eosin staining) will also be eligible.&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Negative pregnancy test done ≤7 days prior to registration, for women of childbearing&#xD;
             potential only.&#xD;
&#xD;
          -  Ability to complete questionnaire(s) by themselves or with assistance.&#xD;
&#xD;
          -  Ability to elect radiotherapy care in conjunction with their physician&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
          -  Willingness to return to enrolling institution for follow-up (during the Active&#xD;
             Monitoring Phase of the study).&#xD;
&#xD;
          -  Willing to provide tissue and blood samples for correlative research purposes&#xD;
&#xD;
          -  Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry&#xD;
             and Biobanking study, IRB number 15-000136&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following because this study involves therapy that has known genotoxic,&#xD;
             mutagenic and teratogenic effects:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
          -  Neoadjuvant chemotherapy&#xD;
&#xD;
          -  Prior history of ipsilateral breast cancer&#xD;
&#xD;
          -  Prior radiation therapy to the ipsilateral breast or thorax&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens.&#xD;
&#xD;
          -  Active collagen-vascular disease that, in the opinion of the treating physician, would&#xD;
             make this protocol unreasonably hazardous for the patient.&#xD;
&#xD;
          -  Paget's disease of the breast&#xD;
&#xD;
          -  Proven multicentric carcinoma (DCIS or invasive) in more than one quadrant or&#xD;
             separated by 4 or more centimeters or diffuse (&gt;1 quadrant) suspicious calcifications&#xD;
&#xD;
          -  Histologic evidence of angiolympatic invasion (ALI). Note: Cases termed focally&#xD;
             suspicious for ALI but where no definitive ALI is found are eligible.&#xD;
&#xD;
          -  Surgical margins that cannot be microscopically assessed or that are positive&#xD;
&#xD;
          -  Pathologic tumor &gt;2cm in size&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Patients for whom the delivery of APBI is not feasible or any of the dosimetric&#xD;
             treatment criteria in section 9.7 have not been met.&#xD;
&#xD;
          -  BRCA 1/2 mutation Note: Patients are not required to undergo BRCA1 and BRCA2 or other&#xD;
             genetic mutation tests in order to enroll on the study. However, in the event a&#xD;
             patient is tested and is found to be a mutation carrier, she would be excluded from&#xD;
             the study.&#xD;
&#xD;
          -  Breast implants (patients who have had implants removed are eligible).&#xD;
&#xD;
          -  Extensive intraductal component&#xD;
&#xD;
          -  Active connective tissue disease&#xD;
&#xD;
          -  Reduction mammoplasty if 3DCRT or proton APBI are planned&#xD;
&#xD;
          -  Last surgery &gt;10 weeks from enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Mutter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Robert Mutter</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Proton</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Partial Breast Irradiation</keyword>
  <keyword>3D Conformal Photon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

